Abstract Search

ey0019.9-1 | Cancer treatment and growth hormone therapy: a consensus | ESPEYB19

9.1. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement

MCS Boguszewski , CL Boguszewski , W Chemaitilly , LE Cohen , J Gebauer , C Higham , AR Hoffman , M Polak , KCJ Yuen , N Alos , Z Antal , M Bidlingmaier , BMK Biller , G Brabant , CSY Choong , S Cianfarani , PE Clayton , R Coutant , AA Cardoso-Demartini , A Fernandez , A Grimberg , K Guðmundsson , J Guevara-Aguirre , KKY Ho , R Horikawa , AM Isidori , JOL Jorgensen , P Kamenicky , N Karavitaki , JJ Kopchick , M Lodish , X Luo , AI McCormack , L Meacham , S Melmed , Moab S Mostoufi , HL Muller , SJCMM Neggers , Oliveira MH Aguiar , K Ozono , PA Pennisi , V Popovic , S Radovick , L Savendahl , P Touraine , HM van Santen , G Johannsson

n.karavitaki@bham.ac.uk Eur J Endocrinol. 2022; 186: P35-P52. PMID: 35319491.Brief Summary: An international panel of experts produced this consensus statement after critical review of the existing evidence on the safety of GH replacement in cancer and intracranial tumour survivors and in patients with increased cancer risk. Current evidence does not support an association betwe...

0 shares

ey0021.9-16 | Bone Health and Chronic Diseases | ESPEYB21

9.16. Vertebral body reshaping after fractures: an important index of recovery in glucocorticoid-treated children

J Ma , K Siminoski , JL Jaremko , K Koujok , MA Matzinger , N Shenouda , N Wilson , M Cheng , N Alos , S Atkinson , EA Cummings , J Ho , C Rodd , AM Sbrocchi , R Stein , R Barr , E Cairney , DB Dix , CV Fernandez , R Grant , J Halton , S Israels , C Laverdiere , VA Lewis , DA Cabral , A Huber , K Houghton , R Jurencak , B Lang , M Larche , CMA LeBlanc , P Miettunen , J Roth , R Scuccimarri , L Bell , T Blydt-Hansen , G Filler , J Feber , V Phan , K Smit , F Rauch , LM Ward

Brief Summary: This prospective natural history study examined the timing and positive indicators for reshaping of vertebral fractures (VF) in glucocorticoid (GC)-treated patients with chronic diseases. Complete VF reshaping occurred in 82.3% of patients, with similar frequencies in all diagnosis groups (leukemia, rheumatic disorders and nephrotic syndrome) in a median time of 1.3 years. Likelihood of VF reshaping was positively related to higher lumbar spine bone mineral dens...

0 shares

ESPE Yearbook of Paediatric Endocrinology

9.1. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement

9.16. Vertebral body reshaping after fractures: an important index of recovery in glucocorticoid-treated children

BiosciAbstracts